Clinical Trial Detail

NCT ID NCT02082210
Title A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

hepatocellular carcinoma

Advanced Solid Tumor

renal cell carcinoma

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma

Therapies

Emibetuzumab + Ramucirumab

Age Groups: adult senior

No variant requirements are available.